Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience
2020 ◽
Vol 15
(3)
◽
2015 ◽
Vol 31
(4)
◽
pp. 439-445
Keyword(s):
Keyword(s):
2020 ◽
Vol 47
(2-3)
◽
pp. 41-47
Keyword(s):